Germany's MedCanG Amendment: What Proposed Prescription Restrictions Mean for Medical Cannabis Exporters

Less than two years after Germany removed medical cannabis from its narcotics schedule and opened prescribing to any licensed physician for any indication, the CDU/CSU-led federal government is proposing to tighten the framework. The draft amendment to the Medical Cannabis Act (MedCanG) would restrict telemedicine prescribing, ban mail-order pharmacy dispensing for cannabis, and limit medical-scientific cannabis use to formal clinical trials only. If it passes, it will reshape the demand dynamics that have driven Germany's import volumes to 201,094 kg in 2025.

The operative word is "if." As of mid-June 2026, the bill has not passed. The SPD, the CDU/CSU's coalition partner, has publicly opposed the draft in its current form. The outcome matters significantly for any operator building a German export program around current prescription volumes. Understanding what is being proposed, where the legislation stands, and what a range of outcomes means for your planning is more useful than reacting to either the alarm or the dismissal.

What the Amendment Proposes

The Federal Cabinet approved the MedCanG draft amendment on October 8, 2025, and submitted it to the European Union for notification under the single-market technical standards process that same month. The EU notification required a three-month standstill period during which EU member states and the Commission could review whether the proposed restrictions affected intra-EU trade. That process completed in early 2026 without objection, meaning Germany is legally cleared to implement once the Bundestag votes.

The core proposals are four. First, new medical cannabis patients must have an in-person initial consultation with a licensed physician before receiving a prescription. Remote consultations via telemedicine platforms would not qualify as a first appointment. Second, repeat prescriptions via telemedicine would be limited to patients who had already completed an in-person initial visit, grandfathering existing patients who established care in person. Third, mail-order pharmacy dispensing of cannabis would be prohibited, though local pharmacy delivery by courier would remain permitted. Fourth, medical and scientific use of cannabis in research contexts would be restricted to formal, approved clinical trials, eliminating informal dispensary-adjacent research frameworks that had emerged under the more permissive CanG regime.

The stated rationale is that telemedicine cannabis prescribing had evolved into a system where patients could receive prescriptions through brief video consultations without the diagnostic rigor expected in conventional pharmaceutical prescribing. Health Minister Nina Warken and the CDU/CSU argued that this was producing a de facto recreational access pathway under a medical label, with reimbursement implications for the statutory health insurance system.

The Legislative Status

The Bundestag held its first reading of the draft bill on December 18, 2025. The parliamentary health committee convened its expert hearing on January 14, 2026. Expert testimony was mixed: organizations representing physicians and pharmacists were broadly supportive of tightening the telemedicine pathway, while cannabis industry associations and patient advocacy groups opposed the restrictions. The committee hearing did not produce a consensus recommendation.

The SPD's position is the decisive variable. Germany's CDU/CSU and SPD are governing in coalition, and the SPD has publicly called for adjustments to the MedCanG amendment draft. Without SPD support, the bill cannot pass the Bundestag with a governing coalition majority. The SPD's objections, as reported through cannabis law commentary, center on the scope of the telemedicine restriction and the practical access implications for patients in rural areas where in-person specialist consultations are difficult to arrange.

As of mid-June 2026, no final vote date has been set. The bill is technically still alive but politically stalled. Germany's drug commissioner has reportedly broken with CDU party orthodoxy by supporting continued cannabis pilot projects, adding further internal fracture to the coalition's position on cannabis regulation. The most likely near-term scenario is continued negotiation between coalition partners on the scope of telemedicine restrictions, potentially producing a narrower version of the amendment that the SPD can accept.

Why Telemedicine and Mail-Order Define the Demand Equation

Germany's 3,300% prescription increase in the 18 months following the CanG's April 2024 passage was not driven primarily by traditional GP-referred patients managing chronic conditions. A significant portion was driven by telemedicine platforms that made cannabis prescriptions accessible without the friction of specialist referrals, long appointment waits, or geographic limitations on pharmacy access. Mail-order pharmacies extended that accessibility by delivering dispensed cannabis to any address in Germany.

The patient population that accessed cannabis through telemedicine and mail-order is not identical to the patient population that would access it through in-person physician consultations. Some telemedicine patients would convert to in-person care. Others, particularly those using cannabis for lifestyle-adjacent conditions that a face-to-face physician would be less likely to prescribe for, would not. Any honest assessment of what the MedCanG amendments would do to total demand has to account for this non-conversion segment.

Independent industry estimates have suggested that the combined telemedicine and mail-order restrictions, if fully implemented, could reduce Germany's active patient count by 20 to 40%, with a corresponding reduction in import volumes. That range is wide because it depends on assumptions about conversion rates and patient behavior that no one has fully measured. At the lower end of the impact range, German imports might moderate from around 200 tonnes annually to roughly 150 tonnes. At the higher end, the reduction could be more pronounced in the near term before the market restabilizes around in-person prescribing channels.

What This Means for Export Planning

The key mistake operators make when responding to regulatory uncertainty like the MedCanG amendment is to plan around either extreme: either ignoring the risk entirely and sizing capacity to current demand, or pulling back from Germany entirely on the assumption that the amendment will devastate the market. Neither is analytically sound.

Even under a scenario where the amendment passes in its current form and reduces demand by 30%, Germany would still represent approximately 140 tonnes of annual medical cannabis imports, well above any other European market. The underlying structural drivers that made Germany significant, mandatory GKV reimbursement, open multi-indication prescribing, a large insured population, are not changed by the MedCanG amendment. They are the floor beneath whatever demand the amendment removes from the telemedicine tier.

The more important strategic question for Thai exporters is not whether Germany's volumes hold at 200 tonnes or moderate to 150 tonnes. It is whether your compliance position qualifies you to compete for any of those tonnes at all. EU-GMP certification is required for entry into German pharmaceutical distribution regardless of whether demand is higher or lower. A Thai operator who is not EU-GMP-certified or who does not have an EU-GMP processing partner loses access to Germany at any demand level.

Operators with 18 to 36 month certification timelines should not pause those timelines to wait for the MedCanG amendment to resolve. By the time EU-GMP certification is in hand, the German market's regulatory shape will be clear and the export window will be open to operators who prepared for it.

The EU Notification Dimension

One procedural point worth understanding: Germany's submission of the MedCanG amendment to the EU for notification under the single-market technical standards process (TRIS procedure) was not ceremonial. Mail-order pharmacy restrictions have single-market implications because EU law protects cross-border pharmacy dispensing within the union. Germany had to formally notify and wait out the standstill period before the restriction could be implemented. The notification passed without the Commission or any member state lodging a substantive objection, meaning the legal path to implementation is clear once the Bundestag votes. What remains is the domestic political vote, not EU approval.

For international operators monitoring German regulatory developments, the TRIS notification completion in early 2026 means that the only barrier to implementation now is SPD coalition agreement. It is a domestic political question, not a European one.

DeeMED tracks European buyer requirements and market access conditions as part of our medical cannabis export consulting work. If you are building a German market entry program and want clarity on how the MedCanG amendment affects your commercial assumptions, reach out directly.